Clinical Trial Update: R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

View source ↗

Summary

This document describes an Expanded Access Protocol for REGN-EB3 to treat Ebola Virus Disease. The protocol is currently available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• REGN-EB3 (REGN3470-3471-3479)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Ebola Virus Disease | Status: AVAILABLE